Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 5/20 | 1.00 |
| ▸ | BBOX1 | O75936 | 4/20 | 1.00 |
| ▸ | THRA | P10827 | 3/20 | 0.70 |
| ▸ | THRB | P10828 | 3/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | ASPH | Q12797 | 1/20 | 0.55 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390250 | 1.00 | EGLN1 (1.00) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL522971 | 0.89 | EGLN1 (0.80) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL25934724 | 0.89 | EGLN1 (0.80) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL523725 | 0.87 | EGLN1 (0.78) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL4082616 | 0.86 | EGLN1 (0.76) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL522699 | 0.86 | EGLN1 (0.74) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL522722 | 0.86 | EGLN1 (0.74) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL966797 | 0.85 | EGLN1 (0.73) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL522079 | 0.84 | EGLN1 (0.72) | EGLN1FTOBBOX1THRATHRB | |
| SCHEMBL29724635 | 0.84 | EGLN1 (0.72) | EGLN1FTOBBOX1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319119-A1 | COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-10-16 | — | — | US | claimed |
| EP-4512819-A2 | COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS | The General Hospital Corporation (US) | 2025-02-26 | — | — | EP | claimed |
| EP-3720468-B1 | TISSUE REPAIR | UNIV SUSSEX (GB) | 2024-10-30 | — | — | EP | claimed |
| US-11596668-B2 | Tissue repair | THE UNIVERSITY OF SUSSEX (GB) | 2023-03-07 | — | — | US | claimed |
| US-20220259559-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING JAG-1 | Frequency Therapeutics, Inc. | 2022-08-18 | — | — | US | claimed |
| WO-2021259471-A1 | DERMAL FILLER WITH HIF-1α ACTIVITY MODULATORS | THOR DOMINIK (AT) | 2021-12-30 | — | — | WO | claimed |
| US-11162071-B2 | Compositions and methods for generating hair cells by upregulating JAG-1 | Frequency Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | claimed |
| CN-113195707-A | Compositions and methods for generating hair cells by upregulation of JAG-1 | 频率治疗公司 | 2021-07-30 | — | — | CN | claimed |
| EP-3837352-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING JAG-1 | Frequency Therapeutics, Inc. (US) | 2021-06-23 | — | — | EP | claimed |
| US-20210162008-A1 | TISSUE REPAIR | THE UNIVERSITY OF SUSSEX (GB) | 2021-06-03 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| US-20060178316-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. (US) | 2006-08-10 | — | — | US | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| EP-0911340-B1 | Substituted Isoquinolin-3-Carboxyamides, their preparation and medical use | FIBROGEN INC (US) | 2005-07-06 | — | — | EP | claimed |
| EP-1538160-A1 | Substituted Isoquinolin-3-carboxyamides, their preparation and medical use | FIBROGEN, INC. (US) | 2005-06-08 | — | — | EP | claimed |
| WO-2005007192-A2 | CYTOPROTECTION THROUGH THE USE OF HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| US-6093730-A | AN ENZYME INHIBITORS OF PROLYL-4-HYDROXYLASE FOR TREATING FIBROTIC DISORDERS AND INHIBITING COLLAGEN BIOSYNTHESIS | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2000-07-25 | — | — | US | claimed |
| EP-0911340-A2 | Substituted Isoquinolin-3-Carboxyamides, their preparation and medical use | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11162071-B2 | Compositions and methods for generating hair cells by upregulating JAG-1 | NOTCH1, HES1, NOTCH3 | EGLN1 430/4885FTO 4587/4885BBOX1 1032/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | EGLN1 16/4885FTO 2804/4885BBOX1 2822/4885 |
| US-20060178316-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | EGLN1 13/4885FTO 2629/4885BBOX1 1073/4885 |
| US-20220259559-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY UPREGULATING JAG-1 | NOTCH1, HES1, NOTCH3 | EGLN1 430/4885FTO 4587/4885BBOX1 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.